Cancer ‘wonder drug’ launched in BritainSeptember 21st, 2011 - 9:46 pm ICT by IANS
London, Sep 21 (IANS) A pill that can help prostate cancer patients live about five months longer was launched in Britain Wednesday.
The drug, Zytiga, developed by British scientists, can increase life expectancy even in men with advanced, aggressive cancers, the express.co.uk reported.
The drug cost 3,000 pounds and is yet to be approved for NHS (National Health Service) prescription.
Until then, patients can ask their doctors, or approach the Cancer Drugs Fund or their Primary Care Trust, for the drug.
Zytiga works by cutting off the tumour’s supply of testosterone, stopping it from growing.
It can be used in up to 80 percent of patients with drug-resistant prostate cancer who have already tried anti-hormonal therapies and chemotherapies, the Express said.
- High level of testosterone may speed up prostate cancer - Jul 31, 2012
- Evidence of unusual drug-resistant breast tumours found - Oct 09, 2010
- Experimental drug for advanced prostate cancer shows promise - Apr 15, 2010
- Combo therapy may overcome Herceptin-resistant breast cancer - Mar 14, 2011
- Pomegranate juice could be key to new cancer therapies - Dec 13, 2010
- Slowing down prostate cancer by starving its cells - Nov 03, 2011
- New method detects aggressive prostate cancer - Aug 09, 2012
- Protein that protects against prostate cancer discovered - Feb 01, 2011
- Pill to fight deadly skin cancer in sight - Jan 20, 2011
- Potent anticancer drug isolated from weed - Jul 10, 2012
- Blood vessels could predict how prostate cancer would behave - Nov 04, 2009
- British 'smart bomb' to target cancer - Jun 30, 2012
- No conclusive evidence to show 'male menopause' exists - Jun 03, 2010
- New cancer vaccine Out - May 03, 2010
- Electric shocks soften up cancer cells for treatment - Dec 07, 2010
Tags: britain london, british scientists, cancer drugs, cancers, doctors, express co, five months, hormonal therapies, life expectancy, national health service, primary care trust, prostate cancer, prostate cancer patients, testosterone, tumour